Mechanistically, CD74 can shape the tumor microenvironment by regulating the development of myeloid cells, possibly by activating the innate immune response, such as interactions among HPCs, malignant cells, macrophages and DCs, thus facilitating immunotherapy for HCC. The gene discussed is CD74; the disease is neoplasm.